Antipsychotic drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma cells

Zongjun Shao, MD, PhD; Lillian E. Dyck, PhD; Haitao Wang, PhD; Xin-Min Li, MD, PhD
Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Sask.

Introduction

Atypical antipsychotic drugs are normally used to treat schizophrenia but, more recently, their usefulness in treating other psychiatric disorders and neurodegenerative diseases, such as Alzheimer’s disease, has been explored. The atypical antipsychotic drugs quetiapine, clozapine and risperidone have been reported to protect cultured PC12 cells from cell death induced by serum withdrawal. Similarly, quetiapine, clozapine, olanzapine and risperidone protect PC12 cells from N-methyl-4-phenylpyridinium ion (MPP⁺)-induced apoptosis.

It has been postulated that targeting the synthesis and secretion of neurotrophic factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and glial cell line–derived neurotrophic factor (GDNF), might be a new approach to treating neurodegenerative and depressive disorders. NGF and BDNF have been implicated in the neuroprotective actions of antipsychotic drugs.

Objective: Atypical antipsychotic drugs have been shown to protect PC12 cells from cell death induced by a variety of stimuli in culture. Recently, it has been postulated that trophic factors, such as brain-derived neurotrophic factor (BDNF), play a role in preventing cell death. It has been shown that antipsychotic drugs attenuate the decrease in rat hippocampal BDNF that results from immobilization-induced stress. We aimed to determine whether the neuroprotective effects of antipsychotic drugs could be mediated through glial cell line–derived neurotrophic factor (GDNF). Methods: We investigated the effects of the atypical antipsychotic drugs quetiapine and clozapine and the typical antipsychotic haloperidol on the secretion of GDNF from rat C6 glioma cells. Results: All 3 drugs increased the amount of GDNF secreted from C6 glioma cells into the medium after 48-hour culture. The intracellular content of GDNF was not altered by treatment with any of the antipsychotic drugs. None of the antipsychotic drugs decreased cell number. Conclusion: This study suggests that stimulation of GDNF release from glial cells by antipsychotic drugs might underlie some of their neuroprotective properties in situ.
trophic factor for dopaminergic and other neurons, has well-documented neuroprotective effects. Antidepressant drugs, but not the typical antipsychotic drug haloperidol, have been reported to increase GDNF release from rat C6 glioma cells.

As outlined here, both atypical antipsychotic drugs and GDNF are neuroprotective agents. The goal of this paper was to determine whether the effects of atypical antipsychotic drugs could be mediated through GDNF. A previous study of the effects of antidepressant and antipsychotic drugs on GDNF used C6 glioma cells, a rich source of GDNF; therefore, in order to compare our data, we also used C6 glioma cells to study the effects of quetiapine and clozapine on GDNF secretion. Haloperidol was included for comparative purposes.

Methods

The rat C6 glioma cell line was obtained from the American type Culture Collection (Manassas, Va.). We used 2 different culture media: Dulbecco’s modified Eagle’s medium (DMEM) and serum-free Opti-MEM (GIBCO, Grand Island, NY). All media contained 100 U/mL of penicillin and 100 µg/mL of streptomycin (GIBCO). Incubations were conducted at 37°C in 5% CO₂ and 95% air.

The C6 cells were grown in DMEM supplemented with 2 mmol/L L-glutamine (GIBCO) and 5% fetal bovine serum (Hyclone, Logan, Utah). Cells were seeded into 6-well plates (Falcon, Franklin Lakes, NJ) at a density of 4 × 10⁵/mL in 1.0 mL of growth medium, allowed to adhere for 24 hours, and then medium was replaced with serum-free Opti-MEM (GIBCO) containing 0.5% bovine serum albumin (BSA) (Sigma Chemical Co., Louis, Mo.). The cells were then incubated for 24 hours. The medium was subsequently replaced with fresh Opti-MEM plus 0.5% BSA (1.0 mL) containing the test drug, and the cells were incubated for 48 hours.

The conditioned medium was aspirated and the GDNF content was measured, as described below. In addition, the intracellular GDNF content was measured. The cells were lysed with the 1% NP-40 lysis buffer provided with the enzyme-linked immunosorbent assay (ELISA) kit.

GDNF protein levels in cell-conditioned media and cell lysates were determined using a GDNF ELISA kit, according to the manufacturer’s instructions (Promega, Madison, Wis.). Briefly, Maxisorp 96-well, flat-bottomed ELISA plates (Nunc, Roskilde, Denmark) were coated with anti-GDNF monoclonal antibody and incubated overnight at 4°C. Samples and standards were incubated at room temperature for 6 hours. The captured GDNF was incubated overnight at 4°C with chicken anti-human GDNF polyclonal antibody. After the plates were washed, horseradish peroxidase–conjugated anti-chicken immunoglobulin G antibody was added to the plates (100 µL per well) and incubated at room temperature for 2 hours. The plates were washed, and the enzyme substrate was added at 100 µL per well. The plates were incubated for 15 minutes at room temperature in the dark. The absorbance at a wavelength of 450 nm was recorded on a microplate reader (Molecular Devices, Sunnyvale, Calif.).

The cell number was determined using a cell-counting assay kit (Dojindo, Gaithersburg, Md.). In this assay, WST-8 (2-[2-methoxy-4-nitrophenyl]-3-[4-nitrophenyl]-5-[2,4-disulfol-phenyl]-2H-tetrazolium, monosodium salt) is reduced by dehydrogenases in the cells to give a soluble yellow-coloured product (formazan). The amount of formazan dye generated by the activity of dehydrogenases is directly proportional to the number of living cells. The sensitivity of the WST-8 kit is higher than that of kits using other tetrazolium salts, such as MTT, XTT or MTS. Briefly, after treatment with quetiapine, clozapine or haloperidol, 10 µL of the Cell Counting Kit-8 solution was added to each well in a 96-well plate. After incubation for 2 hours at 37°C, the absorbance of the samples at a wavelength of 450 nm was measured by a UV Max kinetic microplate reader ( Molecular Devices).

The effects of the drug treatments on C6 glioma cell number and concentrations of GDNF were analyzed by 1-way analysis of variance (ANOVA); then, if a significant F value was obtained, the drug-treated samples were compared with drug vehicle control using the Tukey Honestly Significant Difference (HSD) test.

Results

The amounts of GDNF present in the cell-conditioned medium after treatment for 48 hours with vehicle or with an antipsychotic drug are shown in Figure 1. Treatment with quetiapine at concentrations of 5 µmol/L, 10 µmol/L, 15 µmol/L and 25 µmol/L significantly increased the GDNF content of the conditioned media to 128 (standard error of the mean [SEM] 9.2) pg/mL, 158 (SEM 9.6) pg/mL, 169 (SEM 5.0) pg/mL and 221 (SEM 10.0) pg/mL, respectively, compared with the control value of 45.1 (SEM 5.1) pg/mL (Fig. 1A). Similarly, clozapine at concentrations of 5 µmol/L, 10 µmol/L, 15 µmol/L and 25 µmol/L increased GDNF release significantly to 98.7 (SEM 1.3) pg/mL, 129 (SEM 5.2) pg/mL, 149 (SEM 3.9) pg/mL and 192 (SEM 8.7) pg/mL, respectively, compared with the control value of 57.1 (SEM 3.7) pg/mL (Fig. 1B). Haloperidol at concentrations of 10 µmol/L, 15 µmol/L and 25 µmol/L increased GDNF release significantly from 81.1 (SEM 1.1) pg/mL in the control condition to 126 (SEM 5.5) pg/mL, 139 (SEM 4.2) pg/mL and 219 (SEM 9.7) pg/mL, respectively (Fig. 1C).

The release of GDNF by quetiapine, 25 µmol/L, was measured at different time periods up to 48 hours (Fig. 2). It can be seen that the amount of GDNF released in the presence of quetiapine was significantly increased only at the 48-hour time point compared with the appropriate control (media alone at the same time period).

In order to determine whether the release of GDNF was the result of leakage from damaged cells, we measured the amounts of GDNF located within the C6 cells and the effects of the antipsychotic drugs on cell number. Treating the C6 cells with concentrations of quetiapine, clozapine or haloperidol ranging from 1 µmol/L to 25 µmol/L for 48 hours did not change the amount of GDNF present in the cell lysates compared with controls (Fig. 3).

Treating the cells with quetiapine, clozapine or haloperidol
at concentrations ranging from 1 µmol/L to 25 µM for 48 hours in serum-free conditions had no effect on the cell number compared with vehicle controls (Fig. 4). There was neither an increase nor a decrease in the number of cells, indicating that the antipsychotic drugs had no effect on cell proliferation or cell death.

Discussion

A previous paper investigated the effects of a variety of antidepressant drugs (amitriptyline, clomipramine, mianserin, fluoxetine and paroxetine) and other psychoactive drugs on GDNF secretion from C6 cells. Significant GDNF secretion occurred with antidepressant drug concentrations starting at 10 µmol/L. Similar to our results (see Fig. 1), it was found that haloperidol at a concentration of 1 µmol/L did not cause a significant increase in GDNF secretion.

Our results, however, show that concentrations of the antipsychotic drugs quetiapine, clozapine and haloperidol greater than 1 µmol/L caused relatively substantial, dose-dependent secretion of GDNF from C6 glioma cells. The lowest concentrations of the drugs that significantly increased GDNF release were 5 µmol/L for quetiapine and clozapine, and 10 µmol/L for haloperidol. Although these concentrations may seem high compared with the therapeutic plasma levels, they are similar to the concentrations of antipsychotic drugs reported to increase survival of PC12 cells in culture and to the concentrations of serotonin (100 µmol/L) and antidepressants (1–25 µmol/L) that cause GDNF release from C6 cells. At the highest drug concentration tested (25 µmol/L), quetiapine, clozapine and haloperidol all increased GDNF levels in cell-conditioned medium 3–5 times above control levels (Fig. 1).

The GDNF present in the conditioned medium does not appear to have been the result of leakage from damaged cells, because the drug treatments neither decreased the intracellular GDNF levels (analyzed by lysing the cells and measuring GDNF in the lysates), nor did they decrease the number of C6 cells (Fig. 3 and Fig. 4, respectively). If the GDNF secretion were simply a consequence of leakage from cells damaged by antipsychotic drug treatment, one would
expect to find a decrease in intracellular GDNF levels or a decrease in the number of cells over time compared with controls, or both. Such decreases were not found. Treatment with the antipsychotic drugs at concentrations up to 25 µmol/L neither decreased the amount of GDNF present in the cell lysates, nor decreased the cell number compared with controls. Thus, the GDNF released into the conditioned media does not appear to be the result of leakage from damaged cells. Furthermore, the time course of GDNF release showed

![Graph A](image)

**Fig. 3:** The effects of quetiapine, clozapine and haloperidol on GDNF levels in cell lysates. C6 cells were cultured and treated with different concentrations of (A) quetiapine, (B) clozapine or (C) haloperidol for 48 hours. GDNF protein levels in cell lysates were detected using a GDNF ELISA kit. Values (means and standard error of the mean, n = 3) from 1 of 2 experiments are shown. ELISA = enzyme-linked immunosorbent assay, GDNF = glial cell line–derived neurotrophic factor.

![Graph B](image)

![Graph C](image)

**Fig. 4:** The effects of quetiapine, clozapine and haloperidol on the cell growth of C6 cells cultured in a serum-free system. C6 cells were treated with (A) quetiapine, (B) clozapine or (C) haloperidol for 48 hours. Values (means and standard error of the mean, n = 3) from 1 of 2 experiments are shown.
that a significant release was obtained only after a 48-hour incubation period (Fig. 2). This is the same pattern that was reported for serotonin-stimulated and for antidepressant-stimulated release of GDNF from C6 cells: significant release was observed after 48-hour drug treatment, but not at earlier times.17,18 If leakage of GDNF was occurring, a continuous release over time would be observed.

It has been reported that dopamine itself, several mixed dopamine agonists and dopamine D2 agonists increase GDNF secretion from primary cultures of rodent astrocytes and mesencephalic cells; however, a D3 agonist decreased secretion of GDNF.20–22 It is well known that antipsychotic drugs block D2 receptors. Our results, therefore, that antipsychotic drugs increase GDNF secretion, might involve blocking a D2-inhibition of GDNF secretion.

A recent study showed that serotonin, 100 µmol/L, but not dopamine or noradrenaline, increased the secretion of GDNF from rat C6 cells.23 This effect was partially blocked by inhibition of the mitogen-activated protein (MAP) kinase signalling pathway, but not by inhibition of protein kinase A or protein kinase C. However, inhibition of protein kinase A alone (i.e., not in combination with any other treatment) or the presence of dibutyryl cyclic adenosine monophosphate (cAMP) increased GDNF secretion from C6 glioma cells.24 Thus, it seems that, depending on the experimental conditions, the secretion of GDNF from C6 glioma cells can involve more than one intracellular signalling pathway. It is interesting to note that antipsychotic drugs (olanzapine, risperidone, fluphenazine, clozapine, chlorpromazine) have been reported to have direct effects via a G protein on several signalling cascades, such as those involving Akt and mitogen-activated protein kinase (MEK)/extracellular regulated kinase (ERK), that are important in cell growth and survival.25 The G-protein-coupled receptor that these drugs acted upon was not identified.26 Further studies are necessary to determine whether the antipsychotic drug–stimulated release of GDNF from C6 involves a similar direct effect on the latter pathways.

Although it has been postulated that modulation of the synthesis and secretion of trophic factors such as NGF, BDNF and GDNF by antidepressants might be a novel approach to treating depression, other psychiatric disorders and Parkinson’s disease;27 such a possibility has only recently been considered for antipsychotic drugs.28–30 Our data show that antipsychotic drugs can increase GDNF secretion from C6 glioma cells; this points to a new pathway through which antipsychotic drugs could be neuroprotective. If antipsychotic drugs can also stimulate release of GDNF from glial cells in vivo, this might protect neurons from degeneration associated with diseases such as schizophrenia or Alzheimer’s disease, or degeneration caused by toxic insults such as oxidative stress. Interestingly, R-deprenyl, a putative neuroprotective drug, has been shown to increase GDNF release from cultured mouse astrocytes.28–29

In summary, GDNF release from C6 glioma cells was stimulated by quetiapine and clozapine, at concentrations ranging from 5 µmol/L to 25 µmol/L, and by haloperidol, at concentrations ranging from 10 µmol/L to 25 µmol/L. This increase in GDNF secretion or release by antipsychotic drugs offers a novel mechanism whereby these drugs might act in the treatment of neurodegenerative disorders. Further study is necessary to explore and confirm the exact mechanisms whereby antipsychotic drugs modulate GDNF release from C6 glioma cells.

Acknowledgements: This research was supported by a Canadian Institutes of Health Research/R&D Postdoctoral fellowship to Dr. Shao (200204DFE-102742-UI-CCAA-120040) and by Saskatchewan Health. We would like to thank R. Mag-atas and G. Stegemann for technical assistance and Drs. S. Fedoroff and D. Mousseau for helpful discussion.

Competing interests: None declared for Drs. Shao and Wang. Dr. Dyck has received travel assistance from AstraZeneca. Dr. Li has received a research grant, educational grants for poster presentations and travel assistance from AstraZeneca.

Contributors: Drs. Shao, Dyck and Li conceived and designed the study. Drs. Shao and Wang acquired and analyzed the data. Drs. Shao, Dyck and Li drafted the article, and Drs. Shao, Dyck and Wang revised it. All authors gave final approval for the article to be published.

References


14. Lin LF. Glial cell line-derived neurotrophic factor (GDNF): a com-
Effects of antipsychotic drugs on C6 GDNF release


---

**CANADIAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY**

**29TH ANNUAL MEETING**

Chicago, Illinois
July 9-13, 2006
Lakeside Center at McCormick Place

The 29th Annual Meeting of the CCNP will take place in Chicago from July 9 to 13, 2006. This meeting will be held jointly with the Collegium Internationale Neuro-Psychopharmacologicum (CINP) and will be an excellent opportunity to highlight Canadian neuropsychopharmacology research to our colleagues from around the world. The CCNP will present four symposia and our prestigious Award lectures as part of the meeting program (see http://www.cinp2006.com).

For further information, please contact
Ms. Rachelle Anderson
CCNP Secretariat
1E7.19 Walter MacKenzie Centre
8440-112 St.
Edmonton, Alberta T6G 2B7
Telephone: (780) 407-6543
Email: rmena@ualberta.ca or rmena1@shaw.ca